Chan Whiting
No más puestos en curso
Perfil
Chan Whiting worked as the Director & Head-Immune Monitoring at Aduro BioTech, Inc. and as the Senior Vice President-Research & Development at Tempest Therapeutics, Inc. before obtaining an undergraduate and doctorate degree from the University of California, Los Angeles.
Antiguos cargos conocidos de Chan Whiting.
| Empresas | Cargo | Fin |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/09/2021 |
| CHINOOK THERAPEUTICS, INC. | Director/Miembro de la Junta | - |
Formación de Chan Whiting.
| University of California, Los Angeles | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Chan Whiting
